Literature DB >> 15792529

Bilateral reversible deafness after surgery for unilateral epidermoid tumor: an unusual complication: case report.

Mustafa Efkan Colpan1, Zeki Sekerci, Caglar Berk.   

Abstract

OBJECTIVE AND IMPORTANCE: We present an unusual complication of bilateral hearing loss after surgery for unilateral epidermoid tumor situated at the right pontocerebellar junction. The neurosurgeon must know the possible causes of this catastrophic complication and should take every possible measure to avoid it. CLINICAL
PRESENTATION: A 43-year-old male patient presented with progressive hearing loss in the right ear. A radiological examination demonstrated a mass lesion at the right pontocerebellar junction. A pure tone audiogram revealed sensorineural hearing impairment of the right ear. A brainstem auditory evoked potential test confirmed this with reduced amplitudes and a prolonged I-V interval. INTERVENTION: The patient was operated on via a right paramedian suboccipital craniectomy. The tumor was completely excised, and all of the cranial nerves were preserved during the operation. Postoperatively, the patient developed total bilateral hearing loss, which improved significantly over time.
CONCLUSION: Controlled cerebrospinal fluid drainage during exposure and tumor excision may reduce the possibility of shift and traction on the neural structures and help to prevent ischemic injury. Frequent irrigation of the surgical field and minimizing the spilling of the tumor contents may reduce the risk of chemical irritation. The use of corticosteroids may also help during the postoperative period.

Entities:  

Mesh:

Year:  2005        PMID: 15792529     DOI: 10.1227/01.neu.0000156490.47554.ee

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  1 in total

Review 1.  Progression of Contralateral Hearing Loss in Patients with Unilateral Ear Involvement: A Scoping Review.

Authors:  Marzieh Amiri; Mahdieh Hasanalifard; Fakher Rahim; Alimohamad Asghari; Golshan Mirmomeni; Arash Bayat
Journal:  J Int Adv Otol       Date:  2022-09       Impact factor: 1.316

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.